Myfortic 360 Mg 120 Tablets

Brand : novartis pharmaceuticals

Rs. 3,025.70

Rs. 3,184.90

|

QUICK DELIVERY

Myfortic Specification

Requires Prescription (YES/NO)

Yes

Generics

Mycophenolate Mofetil

Used For

Immunosuppresant

How it works

Mycophenolic acid acts by blocking purine synthesis of human lymphocytes through reversible inhibition of inosine monophosphate dehydrogenase. It also inhibits proliferation of both T- and B- lymphocytes.

Myfortic Usage And Safety

Dosage

Mycophenolate Mofetil

Side Effects

Diarrhoea, vomiting, GI haemorrhage and perforation; leukopenia; asthenia, pain, headache, anaemia, thrombocytopenia, renal tubular necrosis, haematuria, BP changes, hyperglycaemia, disturbances of electrolytes and blood lipids, peripheral oedema, dyspnoea, cough, acne, rash, alopecia, dizziness, insomnia, paraesthesia, tremor, hypersensitivity reactions, pancreatitis, hepatitis. Potentially Fatal: Angioedema, anaphylaxis, fatal pulmonary fibrosis.

Drug Interactions

Aciclovir, valaciclovir, ganciclovir and valganciclovir , colestyramine, magnesium - aluminium hydroxide-containing products, sevelamer and other calcium-free phosphate binders , ciclosporin, metronidazole, quinolones, rifamycins , probenecid. May reduce efficacy of live vaccines.

Indication

It is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycolate should be used concomitantly with cyclosporine and corticosteroids .

When not to Use

Hypersensitive to any of the ingredient , Pregnancy, lactation. Rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), including Kelley-Seegmiller or Lesch-Nyhan syndrome.

Myfortic Precautions

Precaution

Administer under the supervision of a health care provider experienced in immunosuppressive therapy and management of organ transplantation and in an equipped facility .

Myfortic Warnings

Warning 1

Increased risk of lymphoma and increased susceptibility to infection may be related to immunosuppression.

Warning 2

Administration is associated with increased risk of pregnancy loss and congenital malformations. Women of childbearing potential must use contraception .

Warning 3

Perform CBCs weekly during the first month, twice monthly during the second and third months, then monthly through the first year. Monitor patient for signs and symptoms of bacterial, viral, or fungal infections, and for signs and symptoms of organ rejection.